Bayesian Statistics to Reanalyze Data From the STAAMP Trial
Primary result · 30-day mortalityResult — go to the resultHazard ratio 0.81 95% CI 0.59–1.11Authors' conclusion
This quality improvement study using a post hoc bayesian reanalysis of the STAAMP trial suggested a high probability that prehospital TXA would improve survival.
Study context
- Population
- Trauma patients at risk for hemorrhage within ≈2 hours of injury, level I trauma centers in the US, 2015–2019analysed
- Participants
- 903 patients
- Comparison
- Prehospital tranexamic acid (TXA) vs placebo
- TXAn = 447
- Placebon = 456reference
- Primary endpoint
- 30-day mortality (frequentist); posterior probability of mortality benefit (bayesian hierarchical logistic regression, CRASH-2, PATCH-Trauma and noninformative priors)
- Follow-up
- 30 days
Methodological detailspost hoc bayesian reanalysis, multicentre, double-masked, placebo-controlled, phase 3
- Post hoc bayesian reanalysis
- Multicentre
- Double-masked
- Placebo-controlled
- Phase 3
Primary result
30-day mortality
Hazard ratio
0.81
95% CI 0.59–1.11
By group
TXA vs Placebo
HR 0.81 (95% CI 0.59–1.11)
As reported in the abstract
- Posterior RR, CRASH-2 prior
- 0.91 (95% CrI, 0.85-0.97)
- Posterior RR, PATCH-Trauma prior
- 0.80 (95% CrI, 0.65-0.97)
- Posterior RR, noninformative prior
- 0.82 (95% CrI, 0.52-1.23)
- Posterior probability that TXA reduced mortality
- 84% to 99%
Original publication
Bayesian Statistics to Reanalyze Data From the STAAMP Trial. JAMA Netw Open. Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →